The earnings beat and raised EPS guidance are positive, but the revenue guidance cut signals a slower growth trajectory for the core business. Traders should watch for execution on the Biotronik integration and the pace of share repurchases. The FDA approval of EZPLAZ provides a new long-term catalyst, but near-term focus will be on whether the company can stabilize organic growth trends.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $138.89entry
- T+1 · 3mo ago −2.82%α −3.43% · $134.98
- T+5 · 3mo ago −1.09%α −2.31% · $137.37
- T+20 · 3mo ago +0.77%α +0.17% · $139.96
- T+60 · 18d ago +0.63%α +2.30% · $139.77
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Teleflex reported Q2 2026 adjusted EPS of $1.76, a 37.4% beat vs the $1.28 consensus, driven by strong Vascular and Surgical growth and aggressive capital return. However, the company reduced its full-year pro forma adjusted constant currency revenue growth guidance to 3.5%-4.5% (from 4.5%-5.5%) due to slower-than-expected integration of the acquired Biotronik Vascular Intervention business, creating a mixed picture of earnings upside against a top-line growth deceleration.
Key Financial Metrics
Key Facts
- Q2 2026 adjusted EPS of $1.76 beat consensus of $1.28 by 37.4%
- Q2 2026 revenue of $570.3M beat consensus of $559.6M by 1.9%
- Full-year pro forma adjusted constant currency revenue growth guidance reduced to 3.5%-4.5% from 4.5%-5.5%
- Full-year adjusted EPS guidance raised to $6.90-$7.20 from $6.25-$6.55
- Completed $1.5B OEM divestiture; deployed $250M for share repurchases in Q2 and announced a $250M accelerated share repurchase
- Paid off $700M Term Loan A-2 and refinanced credit facilities
- Received FDA BLA approval for EZPLAZ Freeze Dried Plasma
- Integration of Biotronik Vascular Intervention business taking longer than expected, impacting revenue outlook
Financial Impact
Q2 adjusted EPS beat consensus by $0.48 (37.4%); full-year adjusted EPS guidance raised by $0.65 at midpoint; full-year revenue growth guidance reduced by ~100bps at midpoint
Risk Factors
- Slower-than-expected Biotronik integration could lead to further revenue guidance reductions
- Activist investor campaign may create strategic uncertainty or force suboptimal capital allocation
- Execution risk on achieving ~$50M in annualized restructuring savings by mid-2028
- Potential IEEPA tariff refunds are excluded from guidance, creating uncertainty in cash flow
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000096943-26-000091 |
| Exhibit: exhibit992to8-6x2026req2.htm | 0000096943-26-000091 |
| Document: tfx-20260806.htm | 0000096943-26-000091 |
| Document: 0000096943-26-000091-index-headers.html | 0000096943-26-000091 |
| Document: 0000096943-26-000091-index.html | 0000096943-26-000091 |
| Document: 0000096943-26-000091.txt | 0000096943-26-000091 |
| 8-K Data (Synthetic) | 0000096943-26-000091 |
Track record
11 reports on TFX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $154.69 Now $155.10 +0.27% settles Nov 23
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $152.15 to $153.15 Now $155.10 +1.94% ▲ +0.66% −2.63% vs SPY
- Aug 6, 202614w ago 8-K Mixed 6/10 Viewing Entry $138.89 to $137.37 Now $155.10 +11.67% ▼ −1.09% −2.31% vs SPY
- Jul 2, 202619w ago Court Ruling Bullish 6/10 Entry $133.99 to $134.04 Now $155.10 +15.75% ▲ +0.04% −0.89% vs SPY
- Jun 22, 202621w ago Institutional Cluster Mixed 4/10 Entry $121.67 to $129.86 Now $155.10 +27.48% ▲ +6.73% +8.80% vs SPY
- Jun 15, 202622w ago 8-K Neutral 4/10 Entry $127.87 to $124.26 Now $155.10 +21.30% ▼ −2.82% −0.59% vs SPY
- Jun 9, 202622w ago 8-K Neutral 2/10 Entry $132.15 to $127.87 Now $155.10 +17.37% ▼ −3.24% −6.67% vs SPY
- Jun 1, 202624w ago 8-K Neutral 4/10 Entry $127.31 to $129.84 Now $155.10 +21.82% ▲ +1.98% +4.73% vs SPY
- May 27, 202624w ago 8-K Neutral 4/10 Entry $128.90 to $131.04 Now $155.10 +20.32% ▲ +1.66% +1.34% vs SPY
- May 7, 202627w ago 8-K Mixed 6/10 Entry $131.59 to $130.04 Now $155.10 +17.86% ▼ −1.18% −2.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers